Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
RAD VACCINE MIBC trial: what clinicians have said so far
Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer
- NCT05241340 ↗
- Active, not recruiting
- The Methodist Hospital Research Institute
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on RAD VACCINE MIBC (sasanlimab plus stereotactic body radiation therapy in cisplatin-ineligible muscle invasive bladder cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RAD VACCINE MIBC so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase II Clinical Trial of Neoadjuvant Sasanlimab and Stereotactic Body Radiation Therapy as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Urothelial Carcinoma Bladder
- Interventions
- Sasanlimab; Stereotactic Body Radiation Therapy; Radical Cystectomy + pelvic lymph node dissection + urinary diversion
- Arms
- Open arm · Experimental
- Enrollment
- 33 (estimated)
- Primary outcomes
- Composite outcome for Feasibility and Safety
- Clinical benefit rate defined as pathologic complete response (pT0)
- Sponsor
- The Methodist Hospital Research Institute with Pfizer
- Start
- Feb 15, 2022
- Primary completion
- Aug 1, 2025
- Results posted
- No
- Registry record
- NCT05241340 · updated Oct 24, 2025
Publications
linked from the registry- Satkunasivam R, Lim K, Teh BS, Guzman J, Zhang J, Farach A, Chen SH, Wallis CJ, Efstathiou E, Esnaola NF, Sonpavde GP. A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC trial. Future Oncol. 2022 Aug;18(25):2771-2781. doi: 10.2217/fon-2022-0380. Epub 2022 Jun 15. PubMed 35703113